The role of high-flow nasal therapy in bronchiectasis: a post hoc analysis

William R Good; Jeffrey Garrett; Hans U P Hockey; Lata Jayaram; Conroy Wong; Harold Rea

doi:10.1183/23120541.00711-2020

The role of high-flow nasal therapy in bronchiectasis: a post hoc analysis

ERJ Open Res. 2021 Feb 8;7(1):00711-2020. doi: 10.1183/23120541.00711-2020. eCollection 2021 Jan.

Authors

William R Good^{1

2}, Jeffrey Garrett², Hans U P Hockey³, Lata Jayaram^{4

5}, Conroy Wong^{1

2}, Harold Rea^{1

2}

Affiliations

¹ Dept of Medicine, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
² Dept of Respiratory Medicine, Middlemore Hospital, Counties Manukau District Health Board, Otahuhu, New Zealand.
³ Biometrics Matters Ltd, Hamilton, New Zealand.
⁴ Dept of Respiratory Medicine, Western Health, Melbourne, VIC, Australia.
⁵ Melbourne Medical School, The University of Melbourne, Melbourne, VIC, Australia.

Abstract

High-flow nasal therapy significantly reduces exacerbation rates and improves quality of life in patients with stable bronchiectasis. High-flow nasal therapy is therefore a potential treatment option for patients with bronchiectasis. https://bit.ly/2JFXuQc.